

- F-RCZV is a water soluble prodrug of ravuconazole and belongs to the azole class of antifungal drugs.
- Originally discovered by the Japanese pharmaceutical company Eisai.
- In 1996, it was licensed to BMS for worldwide development, excluding Japan.
- In 2004, drug development was terminated by BMS and Eisai reacquired the development and marketing rights.
- In 2018, F-RCZV was approved in Japan for the treatment of onychomycosis (fungal infection of the nail).
- F-RCZV exhibits higher initial cure rates and lower recurrence rates, as well as improved safety profile and dosing regimen (once daily for 12 weeks) over existing standards like itraconazole.




Hata, K. *Antimicrob. Agents Chemother.* **1996**, *40*, 2237. <https://aac.asm.org/content/40/10/2237>
 Yamaguchi, H. *Med. Mycol. J.* **2016**, *57*, 93. <https://doi.org/10.3314/mmj.16-00006>
 Okubo, A. *J. Dermatol.* **2018**, *45*, 1151. <https://doi.org/10.1111/1346-8138.14607>
 Process synthesis: Pesti, J. *Org. Process Res. Dev.* **2009**, *13*, 716. <https://doi.org/10.1021/op900065c>
 DOTW: *The Antifungal Pipeline: Voriconazole and beyond* - Boyko



Bristol-Myers Squibb

Mode of action: inhibits cytochrome P450-dependent 14 α -sterol demethylase preventing the synthesis of ergosterol.



Process synthesis:

